A Phase Ib Study of Pembrolizumab Following Trans-Arterial Chemoembolization in Primary Liver Carcinoma
Latest Information Update: 17 Feb 2023
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Acronyms PETAL
- 13 Feb 2023 Planned End Date changed from 31 Dec 2021 to 31 Dec 2023.
- 13 Feb 2023 Planned primary completion date changed from 31 Dec 2021 to 1 Sep 2023.
- 13 Feb 2023 Status changed from recruiting to active, no longer recruiting.